

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **InvesTech Holdings Limited**

**威訊控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1087)**

### **COMPLETION OF CAPITAL INJECTION**

Reference is made to the Company's announcements dated 17 February 2017, 9 March 2017, 27 March 2017, 27 April 2017, 29 May 2017 and 19 June 2017 and the circular (the "**Circular**") dated 23 June 2017 in relation to the Proposed Capital Injection of RMB600,000,000 from the Company into the Target Company pursuant to the Capital Injection Agreement (as amended and supplemented by the Supplemental Agreement) entered into among the Company, the Target Company and the Target Company's Shareholders on 17 February 2017. Capitalized terms used herein shall have the same meanings as those defined in the Circular unless defined otherwise herein.

Pursuant to the Capital Injection Agreement, the Group shall settle the injection amount within six months after the completion of the relevant registration procedures with the local administration bureau of industry and commerce (the "**Relevant Registration Procedures**") in respect of the Proposed Capital Injection. As the Relevant Registration Procedures have been completed on 29 January 2018, the capital injection amount shall be settled on or before 29 July 2018. The Company is pleased to announced that the capital injection amount has been fully settled and all of the conditions under the Capital Injection Agreement have been fulfilled as at 25 July 2018.

During the Exclusivity Period, the Target Company has introduced two third party investors (the “**Third Party Investors**”) in relation to a capital injection in aggregate of RMB1.6 billion into the Target Company (the “**Subsequent Capital Injection**”). In view that (i) the Target Company has notified the Company the major terms of the Subsequent Capital Injection; (ii) the subscription price borne by the Third Party Investors is equal to that borne by the Company in the Proposed Capital Injection; (iii) the control of the Target Company has remained unchanged upon completion of the Subsequent Capital Injection; and (iv) the aggregated equity interest of the Company in the Target Company was diluted by not more than 1.0% upon completion of the Subsequent Capital Injection, the Subsequent Capital Injection has not violated any provision under the Capital Injection Agreement as set out in the section headed “Exclusivity” in the Circular and therefore the Target Company is not obligated to pay any Compensation Amount to the Company.

As a result of the above, following the Capital Injection Completion and the Subsequent Capital Injection, the Company owns approximately 3.95% of the enlarged registered capital of the Target Company instead of 4.41% as set out in the Circular.

By order of the Board  
**InvesTech Holdings Limited**  
**Chan Sek Keung, Ringo**  
*Chairman and Chief Executive Officer*

Hong Kong, 25 July 2018

*As at the date of this announcement, the executive Directors are Mr. Chan Sek Keung, Ringo (Chairman and Chief Executive Officer), Ms. Wang Fang, Mr. Wu Chi Luen and Mr. Lu Chengye, and the independent non-executive Directors are Mr. Wong Chun Sek, Edmund, Mr. Lu, Brian Yong Chen and Mr. Huang Liangkuai.*